Understand the source comparison
Pe-22-28 FAQ: Research Protocol Comparison
Researchers frequently ask how Pe-22-28 compares to other cognitive research peptides in terms of mechanism, dosing, and study applications. The table below summarizes key differences based on published preclinical data and our experience supporting research f
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers frequently ask how Pe-22-28 compares to other cognitive research peptides in terms of mechanism, dosing, and study applications. The table below summarizes key differences based on published preclinical data and our experience supporting research facilities designing comparative studies.
- Pe-22-28
- BDNF upregulation via TrkB receptor activation; CREB phosphorylation
- 0.5–5mg/kg SC daily
- 4–6 hours
- Hippocampal memory consolidation, spatial learning, neurogenesis
- Best for hippocampal-focused memory research with sustained BDNF effects
- Dihexa
- HGF/c-Met receptor binding; promotes synaptogenesis
- 0.1–1mg/kg SC or oral daily
- 2–3 hours
- Cognitive enhancement, synaptic repair, neurodegenerative models
- Broader synaptic effects but shorter duration; oral bioavailability advantage
- Semax Amidate
- Melanocortin receptor modulation; cortical BDNF upregulation
- 0.3–3mg/kg SC or intranasal daily
- 90 minutes (plasma)
- Attention, stress resistance, stroke recovery
- Faster onset, shorter half-life; cortical rather than hippocampal focus
- Cerebrolysin
- Neurotrophic factor mixture; multi-pathway neuroprotection
- 2.5–5mL/kg IV 5 days/week
- N/A (mixture)
- Traumatic brain injury, Alzheimer's models, stroke
- Clinical-grade neuroprotectant; IV administration limits use in some protocols
- Pe-22-28's 4–6 hour cerebrospinal fluid half-life provides sustained receptor activation that Semax's 90-minute plasma half-life cannot match, making Pe-22-28 better suited for studies requiring consistent BDNF elevation across multi-day behavioral testing windows. Dihexa's oral bioavailability offers convenience, but its HGF/c-Met mechanism produces broader synaptic effects rather than Pe-22-28's targeted hippocampal action. Researchers investigating specific memory pathways often prefer Pe-22-28's selectivity. Cerebrolysin remains the gold standard for neuroprotection studies in acute injury models, but its requirement for intravenous administration and complex neurotrophic factor mixture makes it less practical for mechanistic studies isolating BDNF/TrkB pathways.